Without a doubt, 2020 has been a trying year. The pandemic has touched every business and every human on earth in different ways. And despite all of its tragic outcomes, it has starkly reminded me that we work in one of the most exciting and innovative industries in the world — the life sciences industry.
When this virus became a serious public threat at the beginning of this year, multiple AI companies shifted their focus to using AI to fight coronavirus and their approaches are varied, ranging from drug repurposing to finding novel molecules.
When discussing the role of AI in Covid-19, we have to reframe this conversation and look at AI as an important approach that can provide better analysis and ultimately better outcomes for patients, not as replacing the entirety of the drug discovery process or as a magic bullet for a vaccine.
twoXAR Pharmaceuticals SVP Nonclinical R&D & Chemistry Anjali Pandey moderates a panel including twoXAR CEO Andrew Radin, along with representatives from Recursion Pharma, ATOM Consortium, and NuMedii.